FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4283778802> ?p ?o ?g. }

• W4283778802 endingPage "3256" @default.
• W4283778802 startingPage "3256" @default.
• W4283778802 abstract "In recent years, immunohistochemical protein expression was studied as a surrogate to the molecular classification of bladder cancer, although no tissue biomarkers are available for clinical use to predict survival or the response to neoadjuvant chemotherapy (CT) in UC, as the literature produced conflicting results. This retrospective study included TURB specimens harboring foci of HG pT2 muscle-invasive bladder carcinoma (MIBC) from 251 patients who subsequently underwent radical cystectomy. We performed immunohistochemical analysis on tumor samples, for relevant gene-expression-based markers for basal type (CD44, CK5/6) and luminal type (CK20 and pPARγ). Piescore, investigated in both non-muscle-invasive (NMI) and muscle-invasive (MI) components of the tumor, divided basal and luminal UC-types when at least three of the four markers were consistent with a specific phenotype, mixed types if one/two luminal and basal markers were present simultaneously, and neu-like types when all four markers investigated were negative. Eighteen selected cases were also investigated with RT-PCR to validate, and to increase the specificity of, the immunohistochemical results. We observe an immunophenotypical difference in the NMI and MI components in 96/251 UC patients (38.25%): half of tumors (44/96 cases) have a transition to basal, 36.46% (35/96 cases) to neu-like, 12.5% (12/96 cases) to mixed, and 5.2% (5/96 cases) to luminal phenotypes. Mixed tumors in the NMI component are more likely to change phenotype than other groups, particularly compared with basal tumors, which demonstrate greater stability (only 8/96 cases, p < 0.00001). The transition of luminal tumors to basal display a better OS compared with the transition toward neu-like tumors (p = 0.027). Overall, the phenotypical switch does not affect lymphovascular invasion, pT, DFS, or OS compared with non-switched cases. In the MI component, the presence of CD44 expression, irrespective of score-related phenotype, shows a protective effect in papillary-type UC (OS p = 0.008, HR 0.453, PFS p = 0.07, HR 0.599), and in UC naïve for CT (p = 0.0479). Piescore immunophenotyping reveals an intratumoral phenotypical transition between the NMI and MI components of the same tumor. The molecular change is a common event in the mixed and luminal categories, but not in basal tumors, which show better phenotypical stability. This phenomenon could partially explain the sensitivity of a subset of luminal UC to chemotherapy: good responders could be “non-real” luminal UC, which acquire nasal markers, such as CD44." @default.
• W4283778802 created "2022-07-03" @default.
• W4283778802 creator A5003038893 @default.
• W4283778802 creator A5008118262 @default.
• W4283778802 creator A5018378600 @default.
• W4283778802 creator A5018653210 @default.
• W4283778802 creator A5032746256 @default.
• W4283778802 creator A5048782992 @default.
• W4283778802 creator A5063146246 @default.
• W4283778802 creator A5074349466 @default.
• W4283778802 creator A5074530589 @default.
• W4283778802 creator A5077439295 @default.
• W4283778802 creator A5079571836 @default.
• W4283778802 creator A5081624163 @default.
• W4283778802 creator A5082515771 @default.
• W4283778802 creator A5085558222 @default.
• W4283778802 creator A5087262850 @default.
• W4283778802 date "2022-07-02" @default.
• W4283778802 modified "2023-09-30" @default.
• W4283778802 title "Intratumoral Switch of Molecular Phenotype and Overall Survival in Muscle Invasive Bladder Cancer" @default.
• W4283778802 cites W1968252785 @default.
• W4283778802 cites W1970244281 @default.
• W4283778802 cites W2033775272 @default.
• W4283778802 cites W2086472234 @default.
• W4283778802 cites W2126226944 @default.
• W4283778802 cites W2143077434 @default.
• W4283778802 cites W2162130153 @default.
• W4283778802 cites W2181032107 @default.
• W4283778802 cites W2416106224 @default.
• W4283778802 cites W2416371038 @default.
• W4283778802 cites W2432064225 @default.
• W4283778802 cites W2466866924 @default.
• W4283778802 cites W2544128970 @default.
• W4283778802 cites W2600355028 @default.
• W4283778802 cites W2609787832 @default.
• W4283778802 cites W2611986919 @default.
• W4283778802 cites W2791111208 @default.
• W4283778802 cites W2795679584 @default.
• W4283778802 cites W2796621294 @default.
• W4283778802 cites W2888864474 @default.
• W4283778802 cites W2893724680 @default.
• W4283778802 cites W2915060313 @default.
• W4283778802 cites W2933974970 @default.
• W4283778802 cites W2942769210 @default.
• W4283778802 cites W2944489822 @default.
• W4283778802 cites W2954655827 @default.
• W4283778802 cites W2960850092 @default.
• W4283778802 cites W2970921484 @default.
• W4283778802 cites W2975497362 @default.
• W4283778802 cites W3015939340 @default.
• W4283778802 cites W3026101626 @default.
• W4283778802 cites W3033612535 @default.
• W4283778802 cites W3088966656 @default.
• W4283778802 cites W3131736599 @default.
• W4283778802 cites W4206841660 @default.
• W4283778802 cites W4213214084 @default.
• W4283778802 doi "https://doi.org/10.3390/cancers14133256" @default.
• W4283778802 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35805028" @default.
• W4283778802 hasPublicationYear "2022" @default.
• W4283778802 type Work @default.
• W4283778802 citedByCount "2" @default.
• W4283778802 countsByYear W42837788022023 @default.
• W4283778802 crossrefType "journal-article" @default.
• W4283778802 hasAuthorship W4283778802A5003038893 @default.
• W4283778802 hasAuthorship W4283778802A5008118262 @default.
• W4283778802 hasAuthorship W4283778802A5018378600 @default.
• W4283778802 hasAuthorship W4283778802A5018653210 @default.
• W4283778802 hasAuthorship W4283778802A5032746256 @default.
• W4283778802 hasAuthorship W4283778802A5048782992 @default.
• W4283778802 hasAuthorship W4283778802A5063146246 @default.
• W4283778802 hasAuthorship W4283778802A5074349466 @default.
• W4283778802 hasAuthorship W4283778802A5074530589 @default.
• W4283778802 hasAuthorship W4283778802A5077439295 @default.
• W4283778802 hasAuthorship W4283778802A5079571836 @default.
• W4283778802 hasAuthorship W4283778802A5081624163 @default.
• W4283778802 hasAuthorship W4283778802A5082515771 @default.
• W4283778802 hasAuthorship W4283778802A5085558222 @default.
• W4283778802 hasAuthorship W4283778802A5087262850 @default.
• W4283778802 hasBestOaLocation W42837788021 @default.
• W4283778802 hasConcept C104317684 @default.
• W4283778802 hasConcept C121608353 @default.
• W4283778802 hasConcept C126322002 @default.
• W4283778802 hasConcept C127716648 @default.
• W4283778802 hasConcept C142724271 @default.
• W4283778802 hasConcept C143998085 @default.
• W4283778802 hasConcept C202751555 @default.
• W4283778802 hasConcept C204232928 @default.
• W4283778802 hasConcept C2775910329 @default.
• W4283778802 hasConcept C2778024521 @default.
• W4283778802 hasConcept C2779306644 @default.
• W4283778802 hasConcept C2780352672 @default.
• W4283778802 hasConcept C2780932548 @default.
• W4283778802 hasConcept C55493867 @default.
• W4283778802 hasConcept C71924100 @default.
• W4283778802 hasConcept C86803240 @default.
• W4283778802 hasConceptScore W4283778802C104317684 @default.
• W4283778802 hasConceptScore W4283778802C121608353 @default.
• W4283778802 hasConceptScore W4283778802C126322002 @default.

• next